NASDAQ$GOCO

GoHealth Inc · Q1 2025 earnings

Q1 2025 earnings · · Before market open · Investor relations

Briefing

GoHealth reported Q1 2025 net revenues of $221.0M with a net loss of $9.8M and diluted loss per share of $0.52.

Net revenues increased to $221.0 million from $185.6 million a year ago as Medicare enrollment activity improved. The company posted a net loss of $9.8 million ($0.52 diluted loss per Class A share) versus a larger loss in the prior-year quarter. Adjusted EBITDA and submission economics remain focal points in MD&A.

  • Q1 net revenues $221.0M (+19% YoY).
  • Net loss $9.8M; diluted loss per share $0.52.
  • Medicare Advantage enrollment season drove revenue.
  • Non-controlling interest and preferred dividends affect common EPS.

Headline financials

Total Revenue

$221M

Previous: $186M+19.1%
EPS (adj)

-$0.52

Previous: -$1.04+50.0%
Adjusted EBITDA Margin

19.0%

Previous: 14.5%+31.0%
EBITDA

$33.7M

Previous: $22.8M+48.1%
Adjusted EBITDA

$42.1M

Previous: $26.9M+56.4%
Sales per Submission

$724.00

Previous: $856.00-15.4%
Direct Operating Cost per Submission

$522.00

Previous: $640.00-18.4%
Submissions

303.0K

Previous: 216.1K+40.2%
Net Income

-$4.41M

Previous: -$9.22M+52.2%
Operating Income

$6.67M

Previous: -$4.03M+265.4%

Revenue & EPS history

GoHealth · Revenue · Quarterly

$221M

Q1 2025+19.1%vs Q1 2024
Beat estimate in 5 of 14 quarters(36%)
ActualEstimate

Revenue by segment

GoHealth · $11.9M total across 4 segments · Q1 2026

  • Medicare Agency Revenue
    $9.8M
  • Other Non-Agency Revenue
    $1.76M
  • Medicare Non-Agency Revenue
    $200K
  • Other Agency Revenue
    $155K

Forward guidance

Outlook emphasizes clinical milestones, liquidity runway, and cost discipline.

Tailwinds

  • Pipeline readouts and partnership economics.
  • Cash balance supports near-term development plans.

Headwinds

  • Operating losses and trial risk until commercialization.
  • Financing markets and competition affect funding costs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

-7.7%

Avg return

Earnings day

-9.7%

Avg return

5 days after

-6.6%

Avg return

30 days after

26%

6 / 23 earnings

Positive

+32.2%

Q1 2023

Best reaction

-45.5%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.5%-23.4%
Q3 2025-24.4%-32.0%-12.8%
Q2 2025-9.0%-7.6%-23.8%
Q1 2025-0.6%-17.4%-21.4%
Q4 2024-14.4%-14.9%-32.8%
Q3 2024-6.6%-0.4%-15.4%
Q2 2024-21.4%-28.3%-34.0%
Q1 2024-8.0%-11.1%+2.2%
Q4 2023-13.0%-25.7%-27.0%
Q3 2023+2.3%+6.7%+7.4%
Q2 2023+6.8%+6.3%-17.2%
Q1 2023+32.2%+44.8%+99.5%
Q4 2022-19.9%-6.2%-18.5%
Q3 2022-16.7%-9.4%+95.3%
Q2 2022-31.5%-43.3%-57.0%
Q1 2022+11.1%+4.9%+6.5%
Q4 2021+23.7%+37.7%-9.8%
Q3 2021+1.1%-4.7%-18.1%
Q2 2021-45.5%-42.2%-34.7%
Q1 2021-2.7%-5.6%-4.0%
Q4 2020-14.9%-16.9%-4.1%
Q3 2020-14.9%-15.1%+1.8%
Q2 2020-10.5%-18.5%-27.1%
Q1 2020
Q4 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro